Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHAST-TSC: TSC for Acute Stroke
NCT03763929Phase 2Terminated
- Sponsor
- Diffusion Pharmaceuticals Inc.
- Start
- Aug 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute stroke comparing Trans Sodium Crocetinate with Placebo (2 arms). Primary endpoint: Modified Rankin Scale at 90 days. Started Aug 2019; status: terminated.
02
Drugs
trans sodium crocetinate
03
Conditions
acute stroke
Beyond the preview
Go deeper on NCT03763929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03763929.